Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors

Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. on behalf of investors who acquired shares during the specified class period [1][2] Group 1: Legal Investigation - The investigation focuses on claims that Spectrum made false or misleading statements regarding its Pinnacle Study, a clinical trial for the drug poziotinib aimed at treating certain lung cancer patients [3] - Investors who purchased Spectrum securities between March 17, 2022, and September 22, 2022, are eligible to seek appointment as lead plaintiff representative by the deadline of September 24, 2025 [2] Group 2: Company Background - Spectrum Pharmaceuticals is a biopharmaceutical company that specializes in oncology treatments [2] - Following a merger with Assertio Holdings, Inc., Spectrum shares were delisted [3]